Yuchen Guo, Ph.D.

郭雨辰

Position：

Assistant Professor

Email：

ycguo@shsci.org

Research/Work Experience:

2019-2022 Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine

Education:

2014-2018 University of Montpellier         Ph.D.

2011-2014 Fudan University                M.S.

2007-2011 Shandong Normal University      B.S

Research Interest:

The roles of RNA modification in tumor immunity.

Publication:

1.     Yuchen Guo#, Monica Gabola#, Rossano Lattanzio, Conception Paul, Valérie Pinet, Ruizhi Tang, Hulya Turali, Julie Bremond, Ciro Longobardi, Chloé Maurizy, Quentin Da Costa, Pascal Finetti, Florence Boissière-Michot, Benjamin Rivière, Céline Lemmers, Séverine Garnier, François Bertucci, Inti Zlobec, Karim Chebli, Jamal Tazi, Rania Azar, Jean-Marie Blanchard, Peter Sicinski, Emilie Mamessier*, Bénédicte Lemmers*, Michael Hahne*. Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. J Clin Invest. 2021; 131(4): e131517.

2.     Yuchen Guo#, Jun Wang#, Bente Benedict#, Chen Yang#, Frank van Gemert, Xuhui Ma, Dongmei Gao, Hui Wang, Shu Zhang, Cor Lieftink, Roderick L. Beijersbergen, Hein te Riele, Xiaohang Qiao, Qiang Gao, Chong Sun, Wenxin Qin, René Bernards*, Cun Wang*. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Medicine. 2021; 13(1): 166.

3.     Chen Yang#, Yuchen Guo#, Ruolan Qian#, Yiwen Huang, Linmeng Zhang, Jun Wang, Xiaowen Huang, Zhicheng Liu, Wenxin Qin, Cun Wang*, Huimin Chen*, Xuhui Ma*, Dayong Zhang*. Mapping the landscape of synthetic lethal interactions in liver cancer. Theranostics. 2021; 11(18): 9038-9053.

4.     Yuchen Guo#, Yangyang Zhou#, Wenxin Qin*. A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer. Cancer Biol Med. 2021; 19(2): 136-139.

5.     Haojie Jin#, Yaoping Shi#, Yuanyuan Lv#, Shengxian Yuan#, Christel F. A. Ramirez, Cor Lieftink, Liqin Wang, Siying Wang, Cun Wang, Matheus Henrique Dias, Fleur Jochems, Yuan Yang, Astrid Bosma, E. Marielle Hijmans, Marnix H. P. de Groot, Serena Vegna, Dan Cui, Yangyang Zhou, Jing Ling, Hui Wang, Yuchen Guo, Xingling Zheng, Nikita Isima, Haiqiu Wu, Chong Sun, Roderick L. Beijersbergen, Leila Akkari, Weiping Zhou*, Bo Zhai*, Wenxin Qin*, René Bernards*. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021,595(7869):730-734.